Clinical trials: Neoplasms, Solid Tumor
Solid Tumors
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
The goal of this trial is to learn about the antibody acasunlimab (an antibody also known as GEN1046) when it is used alone and when it is used together with standard of care treatment (docetaxel) or another antibody cancer drug…
- Trial name
- NCT03917381
- Testing
- Acasunlimab, Acasunlimab in combination with docetaxel (in a single expansion cohort), Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)
- Where
- 57 sites in United States, Czechia and 8 more
- Volunteers
- 429 people
- Sponsor
- Genmab
Solid Tumours
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors
This clinical study is being conducted at two sites to determine the optimum dose, safety, and tolerability of oral daily GSK1363089 treatment in adults with solid tumors. This study is no longer recruiting subjects.
- Trial name
- NCT00743067
- Testing
- GSK1363089 (formerly XL880)
- Volunteers
- 37 people
- Sponsor
- GlaxoSmithKline
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Digital Meditation for Postoperative Pain Control After Abdominal Surgery for Cancer
This phase I trial tests a digital meditation for postoperative pain control after abdominal surgery for cancer. Mindfulness interventions such as guided meditation may improve pain control and decrease stress.
- Trial name
- NCT05346692
- Testing
- Survey Administration, Interview, Text Message-Based Navigation Intervention
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Emory University
Solid Tumor (Phase I), RAS Mutation
A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression
The goal of this clinical trial is to determine whether AN4035 is safe and tolerable in people with advanced or metastatic solid tumors that have Rat Sarcoma oncogene (RAS) mutated solid tumors and high levels of the CEACAM5…
- Conditions
- Solid Tumor (Phase I), RAS Mutation, CEACAM5
- Trial name
- NCT07686445
- Testing
- Intravenous AN4035, Intravenous AN4035 followed by intravenous EGFR Inhibitor.
- Where
- 2 sites in Australia
- Volunteers
- 228 people
- Sponsor
- Adlai Nortye Biopharma Co., Ltd.
Advanced Malignancy, Lymphoma
Bevacizumab and Bortezomib in Patients With Advanced Malignancy
The goal of this clinical research study is to find the highest tolerable dose of Avastin™ (bevacizumab) and Velcade™ (bortezomib) that can be given in combination to patients with a metastatic or unresectable advanced…
- Conditions
- Advanced Malignancy, Lymphoma, Myeloma, Solid Tumors
- Trial name
- NCT00428545
- Testing
- Bevacizumab, Bortezomib
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm
Radiosurgery Before Surgery for the Treatment of Brain Metastases
This early phase I trial identifies the side effects of stereotactic radiosurgery before surgery in treating patients with cancer that has spread to the brain (brain metastases).
- Trial name
- NCT04895592
- Testing
- Dexamethasone, Resection, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Emory University
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless…
- Trial name
- DPT01 (NCT04639219)
- Testing
- Trastuzumab deruxtecan
- Where
- 30 sites in United States, Belgium and 7 more
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Advanced Solid Tumors
Dose-finding Study of CAELYXTM and RAD001 in Patients With Advanced Solid Tumors
This is a dose finding, open-label, uncontrolled, dose-escalation trial to determine the Maximum Tolerated Dose (MTD) and the Recommended Dose (RD) of the combination RAD001 (escalating daily dose) and CaelyxTM (fixed dose) to…
- Trial name
- NCT01148628
- Testing
- RAD 001 in combination with Caelyx
- Where
- 3 sites in Italy, Switzerland
- Volunteers
- 54 people
- Sponsor
- Southern Europe New Drug Organization
Neoplasms
Japanese Phase 1 Study of BMS-844203 (CT322)
The purpose of this clinical study is to evaluate the safety and tolerability of CT-322 monotherapy to determine the recommended dose for phase II and subsequent studies
- Trial name
- NCT01146171
- Testing
- BMS-844203 (CT-322)
- Where
- Japan
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors
A Study of the Safety and Efficacy of the Intravenous and Intratumoral Injection of OVV-01 in Patients With Advanced Solid Tumours.
This is an open-label, single-arm, dose escalation clinical study to evaluate the safety and preliminary efficacy of OVV-01 Injection in patients with advanced solid tumors, following both intravenous (iv.) and intratumoral (it.)…
- Trial name
- NCT07648472
- Testing
- OVV-01 Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Joint Biosciences Ltd.
Metastatic Cancer
An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid Tumors
This is an open-label study to evaluate the safety and the anti-tumor activity of the combination of nivolumab and celecoxib. The total numbers of participants to be enrolled will be up to 68 participants, depending on the…
- Trial name
- NICE-COMBO (NCT03864575)
- Testing
- Celecoxib 400 mg
- Where
- Belgium
- Volunteers
- 68 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Gastrointestinal Tumors, Solid Tumors
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
This study is an open, multicenter, non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M24D1 for Injection in patients with locally advanced…
- Trial name
- NCT07279428
- Testing
- BL-M24D1
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Solid Tumors
A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors
This study is a Phase 1/2, first-in-human, open-label, dose-escalation and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, preliminary antitumor activity and immunogenicity of 9MW2821…
- Trial name
- NCT05216965
- Testing
- 9MW2821
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Advanced Cancer
Treatment of Carrying TP53 Harmful Mutations
Assessment of the safety and tolerability of Fluzoparib combined with Apatinib in the treatment of advanced refractory solid tumors with TP53 harmful mutations.
- Trial name
- NCT03645200
- Testing
- Fluzoparib combined with Apatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Second Hospital
Recurrent Solid Tumor, Recurrent Ewing Sarcoma
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away).
- Conditions
- Recurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Malignant Germ Cell Tumor
- Trial name
- NCT04901702
- Testing
- Onivyde, Talazoparib, Temozolomide
- Where
- 10 sites in United States, Canada
- Volunteers
- 90 people
- Sponsor
- St. Jude Children's Research Hospital
Metastatic Solid Tumor
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141
This is a Phase I study designed to evaluate if ASD141 is safe, tolerable, and efficacious in participants with advanced solid tumors.
- Trial name
- NCT06235437
- Testing
- ASD141
- Where
- 2 sites in Taiwan
- Volunteers
- 21 people
- Sponsor
- Ascendo Biotechnology Co., Ltd.
Solid Tumor Refractory to Conventional Treatment
Phase I Study of FXS887 in the Treatment of Solid Tumors
This is a single-arm, open-label, dose-escalation and dose-expansion Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of FXS887 in patients with advanced solid tumors.
- Trial name
- FXS887-I101 (NCT07345637)
- Testing
- FXS887
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
This phase II MATCH treatment trial identifies the effects of GDC-0032 (taselisib) in patients whose cancer has a genetic change called PIK3CA mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439175
- Testing
- Taselisib
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Colorectal Cancer
AI-Assisted Chemotherapy Side Effect Management
This two-stage adaptive randomized controlled trial evaluates the feasibility and preliminary efficacy of large language model (LLM)-assisted intervention for managing chemotherapy side effects in patients with solid tumors.
- Trial name
- ALLIANCE (NCT07198581)
- Testing
- LLM-assisted chemotherapy side effect management
- Where
- South Korea
- Volunteers
- 174 people
- Sponsor
- Incheon St.Mary's Hospital
Advanced Solid Tumor Cancers, Medulloblastoma
An East Asian Study of LDE225
The purpose of this study is to determine Maximum Tolerated Dose (MTD) or recommended phase II dose of LDE225 when administered orally to two adult patient groups of East Asian (i.e., Japanese and Chinese/Taiwanese) with advanced…
- Conditions
- Advanced Solid Tumor Cancers, Medulloblastoma, Basal Cell Carcinoma
- Trial name
- NCT01208831
- Testing
- LDE225
- Where
- 4 sites in Hong Kong, Japan and 1 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.